Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT04319601
Status
Unknown

Conditions

  • Angioimmunoblastic T-cell Lymphoma
  • Chemotherapeutic Toxicity
  • Chemotherapy Effect

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL.

Key Dates

Start date
Mar 13, 2020
Status verified
Mar 2020
Primary completion
Mar 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
26 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: rituximab combined with chidamde and lenalidomide
    rituximab and chidamide, lenalidomide

Primary Outcome Measure

PFS [ Time Frame: From enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 32 months ]

Central Contacts

Related Studies